Akèy › Karsinòm Nèwo-endokrin › Tennessee › Nashville
Etid klinik pou Karsinòm Nèwo-endokrin nan Nashville, TN
3 etid pou Karsinòm Nèwo-endokrin ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI), Nashville
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute - Oncology Partners, Nashville
Etid Karsinòm Nèwo-endokrin nan lòt vil
- Houston, TX6 etid
- New York City, NY6 etid
- Arlington, VA5 etid
- Dallas, TX4 etid
- Los Angeles, CA4 etid
- Washington, DC4 etid
- Columbus, OH3 etid
- St. Louis, MO3 etid
- Grand Rapids, MI3 etid
- Atlanta, GA3 etid
- Denver, CO3 etid
- New Haven, CT3 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.